News Headlines Article

For diabetes drug Avandia, bad news continues
Los Angeles Times

The diabetes drug Avandia, once the world’s top-selling diabetes medication, took two more hits Monday with one new study linking it to an increased risk of heart attacks and a separate study linking it to an increased risk of heart failure and stroke. The research comes only weeks before an upcoming federal hearing to reconsider its fate.

The drug, also known by its generic name, rosiglitazone, was approved in 1999 to help people with Type 2 diabetes control their blood sugar.

Commands